Credelio (5.5 - 11 kg)

3 x 1 pc

Chewable tablet

Active substance

Lotilaner : 225 mg

ATC code

QP53BE04 Lotilaner

QP53BE Isoxazolines

QP53B Ectoparasiticides for systemic use

QP53 Ectoparaciticides, insecticides and repellents

QP Antiparasitic products, insecticides and repellents

Species

Dogs

Indications

For the treatment of flea and tick infestations in dogs.

This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

For the treatment of demodicosis (caused by Demodex canis).

Dose to be administered and administration route

For oral use.

The veterinary medicinal product should be administered in accordance with the following table to ensure a dose of 20 to 43 mg lotilaner/kg bodyweight.

Body weight of dog (kg)	Strength and number of tablets to be administered
Body weight of dog (kg)	Credelio 56 mg	Credelio 112 mg	Credelio 225 mg	Credelio 450 mg	Credelio 900 mg
1.3–2.5	1
>2.5–5.5		1
>5.5–11.0			1
>11.0–22.0				1
>22.0–45.0					1
>45	Appropriate combination of tablets

Use an appropriate combination of available strengths to achieve the recommended dose of 20– 43 mg/kg.

Credelio is a palatable chewable flavoured tablet. Administer the chewable tablet(s) monthly with or after food.
For the treatment of demodicosis (caused by Demodex canis):
Monthly administration of the product for two consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until two negative skin scrapings are obtained one month apart. Severe cases may require prolonged monthly treatments. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.

Adverse reactions

Mild and transient gastrointestinal signs (vomiting; diarrhoea; anorexia) and lethargy have been reported very rarely based on post-marketing safety experience. These signs typically resolve without treatment.

Neurological disorders such as tremor, ataxia or convulsion may occur in very rare cases. In most cases these signs are transient.

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).